Radioprotective gene therapy through retroviral expression of manganese superoxide dismutase.
AuthorsSouthgate, Thomas D
Milsom, Michael D
Ward, Timothy H
Mairs, Robert J
Fairbairn, Leslie J
AffiliationCancer Research UK Gene Therapy Group, Paterson Institute for Cancer Research, Wilmslow Road, Manchester M20 4BX, UK. Tsouthgate@picr.man.ac.uk
MetadataShow full item record
AbstractBACKGROUND: Radiotherapy for the control of cancer, either alone or in conjunction with chemotherapy, is often limited by normal tissue toxicity including haematopoietic toxicity. Exposure of cells to ionizing radiation leads to the formation of reactive oxygen species that are associated with radiation-induced cytotoxicity. The antioxidant enzyme manganese superoxide dismutase (SOD2) catalyzes the dismutation of the superoxide anions into hydrogen peroxide. METHODS: We have investigated the potential of SOD2 overexpression, through retroviral gene transfer using a retrovirus optimized for transcription in early haematopoietic cells, to enhance the radioresistance of a human erythroleukaemic cell line and primary murine bone marrow. Using these as in vitro models we have investigated whether SOD2 gene therapy may be suitable for the protection of the haematopoietic compartment from the effects of ionizing radiation. RESULTS: Here we demonstrate using both biological and physical assays that overexpression of SOD2 protects haematopoietic cells from ionizing radiation injury. Our results show that an increase in the levels of SOD2 enzymatic activity within K562 cells (from 160.7 +/- 23.6 to 321.8 +/- 45.2 U/mg protein) or primary murine haematopoietic progenitor cells leads to both a significant decrease in DNA fragmentation and a significant increase in clonogenic survival, as evident by a significant increase in Dbar (from 2.66 to 3.42Gy), SF2 (from 0.52 to 0.73) values, and a significant decrease in the alpha value (from 0.3040 +/- 0.037 to 0.0630 +/- 0.037 Gy(-1)) when compared either to cells transduced with a retroviral vector encoding eGFP alone or to the parental line. CONCLUSIONS: The results presented suggest that retroviral radioprotective gene therapy may be applicable to the haematopoietic compartment, enabling radiation dose escalation in cancer therapy.
CitationRadioprotective gene therapy through retroviral expression of manganese superoxide dismutase. 2006, 8 (5):557-65notJ Gene Med
JournalThe Journal of Gene Medicine
- Radiosensitive gene therapy through imRNA expression for silencing manganese superoxide dismutase.
- Authors: Qu Y, Zhao S, Hong J, Tang S
- Issue date: 2010 Jun
- Intraoral manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) radioprotective gene therapy decreases ionizing irradiation-induced murine mucosal cell cycling and apoptosis.
- Authors: Epperly MW, Carpenter M, Agarwal A, Mitra P, Nie S, Greenberger JS
- Issue date: 2004 Jul-Aug
- Role of manganese superoxide dismutase in radioprotection using gene transfer studies.
- Authors: Suresh A, Tung F, Moreb J, Zucali JR
- Issue date: 1994 Jun
- Mitigation of radiation-induced skin injury by AAV2-mediated MnSOD gene therapy.
- Authors: Yan S, Brown SL, Kolozsvary A, Freytag SO, Lu M, Kim JH
- Issue date: 2008 Sep
- Effects of MnSOD-plasmid liposome gene therapy on antioxidant levels in irradiated murine oral cavity orthotopic tumors.
- Authors: Epperly MW, Wegner R, Kanai AJ, Kagan V, Greenberger EE, Nie S, Greenberger JS
- Issue date: 2007 Mar